Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
Open accessThe DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Abstract
Human coronaviruses (hCoVs) can be divided into low pathogenic and highly pathogenic coronaviruses. The low pathogenic CoVs infect the upper respiratory tract and cause mild, cold-like respiratory illness. In contrast, highly pathogenic hCoVs such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) predominantly infect lower airways and cause fatal pneumonia. Severe pneumonia caused by pathogenic hCoVs is often associated with rapid virus replication, massive inflammatory cell infiltration and elevated pro-inflammatory cytokine/chemokine responses resulting in acute lung injury (ALI), and acute respiratory distress syndrome (ARDS). Recent studies in experimentally infected animal strongly suggest a crucial role for virus-induced immunopathological events in causing fatal pneumonia after hCoV infections. Here we review the current understanding of how a dysregulated immune response may cause lung immunopathology leading to deleterious clinical manifestations after pathogenic hCoV infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latter promoting lung injury and respiratory failure [22,23].”
From Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection (2020) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.003 · Cited by 2,948
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
Self-citationCoronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Self-citation
Research works printed but not linked: 2
- Masters PS, Perlman, S (2013) Coronaviridae. In: Knipe DM, Howley P (eds) Fields Virology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 825–858
- van den Brand JM et al (2014) The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol 151(1):83–112 · DOI · Paper page
Cited by
Items 101–143 of 143
Collapsing Glomerulopathy in a Patient With COVID-19
Larsen, C. P., Bourne, T. D., Wilson, J. D., Saqqa, O., & Sharshir, M. A. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.04.002 · Cited by 314
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., De Santis, M., Acosta-Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 312
Coronavirus 2019-nCoV: A brief perspective from the front line
Han, Q., Lin, Q., Jin, S., & You, L. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.010 · Cited by 308
Girija, A. S. S., Shankar, E. M., & Larsson, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01206 · Cited by 308
Kirtipal, N., Bharadwaj, S., & Kang, S. G. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104502 · Cited by 306
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 296
Type I and III interferon responses in SARS-CoV-2 infection
Kim, Y.-M., & Shin, E.-C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00592-0 · Cited by 296
The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients
Hariharan, A., Hakeem, A. R., Radhakrishnan, S., Reddy, M. S., & Rela, M. (2021) · Inflammopharmacology · doi:10.1007/s10787-020-00773-9 · Cited by 295
AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype
Wu, H., Larsen, C. P., Hernandez-Arroyo, C. F., Mohamed, M. M. B., Caza, T., Sharshir, M., Chughtai, A., Xie, L., Gimenez, J. M., Sandow, T. A., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050558 · Cited by 282
Bae, S., Kim, S. R., Kim, M.-N., Shim, W. J., & Park, S.-M. (2021) · Heart · doi:10.1136/heartjnl-2020-317901 · Cited by 280
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30277-0 · Cited by 275
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Capra, R., De Rossi, N., Mattioli, F., Romanelli, G., Scarpazza, C., Sormani, M. P., & Cossi, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.009 · Cited by 271
Liu, Y., Zhang, C., Huang, F., Yang, Y., Wang, F., Yuan, J., Zhang, Z., Qin, Y., Li, X., Zhao, D., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa037 · Cited by 269
Poggiali, E., Zaino, D., Immovilli, P., Rovero, L., Losi, G., Dacrema, A., Nuccetelli, M., Vadacca, G. B., Guidetti, D., Vercelli, A., et al. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.012 · Cited by 266
Boudewijns, R., Thibaut, H. J., Kaptein, S. J. F., Li, R., Vergote, V., Seldeslachts, L., Van Weyenbergh, J., De Keyzer, C., Bervoets, L., Sharma, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19684-y · Cited by 263
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 262
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Manson, J. J., Crooks, C., Naja, M., Ledlie, A., Goulden, B., Liddle, T., Khan, E., Mehta, P., Martin-Gutierrez, L., Waddington, K. E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30275-7 · Cited by 258
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis
Wilson, J. G., Simpson, L. J., Ferreira, A.-M., Rustagi, A., Roque, J., Asuni, A., Ranganath, T., Grant, P. M., Subramanian, A., Rosenberg-Hasson, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140289 · Cited by 256
Chemokines and chemokine receptors during COVID-19 infection
Khalil, B. A., Elemam, N. M., & Maghazachi, A. A. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.034 · Cited by 249
“Collectively, these chemokines further increase the accumulation of pathogenic IMMs which in turn produce pro-inflammatory cytokines such as TNF-a, IL-6, or IL-1b leading to T cell apoptosis and impeding virus clearance [72,83].”
Borges, L., Pithon-Curi, T. C., Curi, R., & Hatanaka, E. (2020) · Mediators of Inflammation · doi:10.1155/2020/8829674 · Cited by 235
“TLR stimulation activates the nuclear factor-κB (NF-κB) signaling cascade, causing the production of inflammatory markers from monocytes (interleukin- (IL-) 1, tumor necrosis factor-alpha (TNF-α), and IL-6) to control virus infections [8] by direct antiviral pathways and the recruitment of other leukocytes [10].”
BackgroundBellmann-Weiler, R., Lanser, L., Barket, R., Rangger, L., Schapfl, A., Schaber, M., Fritsche, G., Wöll, E., & Weiss, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082429 · Cited by 244
“This is in accordance with the association of altered iron homeostasis with more advanced inflammation, the latter promoting lung injury and respiratory failure [22,23].”
ResultAlijotas-Reig, J., Esteve-Valverde, E., Belizna, C., Selva-O'Callaghan, A., Pardos-Gea, J., Quintana, A., Mekinian, A., Anunciacion-Llunell, A., & Miró-Mur, F. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102569 · Cited by 235
“In addition, CyA and tacrolimus downmodulated the calcineurin/Nuclear Factor of activated-T cells inflammatory pathway induced by SARS- [46,47].”
Zhang, M., Wang, P., Luo, R., Wang, Y., Li, Z., Guo, Y., Yao, Y., Li, M., Tao, T., Chen, W., et al. (2021) · Advanced Science · doi:10.1002/advs.202002928 · Cited by 236
Hariyanto, T. I., Japar, K. V., Kwenandar, F., Damay, V., Siregar, J. I., Lugito, N. P. H., Tjiang, M. M., & Kurniawan, A. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.12.076 · Cited by 218
“Studies also suggest that under inflammatory conditions, dysregulation of the coagulation cascade in SARS-CoV-2 infection results in diffuse alveolar damage with cellular fibromyxoid exudates, pneumocyte desquamation, and formation of a hyaline membrane, pulmonary edema with hyaline membrane formation, and interstitia…”
BackgroundCOVID-19 revisiting inflammatory pathways of arthritis
Schett, G., Manger, B., Simon, D., & Caporali, R. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0451-z · Cited by 191
The pulmonary pathology of COVID-19
Bösmüller, H., Matter, M., Fend, F., & Tzankov, A. (2021) · Virchows Archiv · doi:10.1007/s00428-021-03053-1 · Cited by 180
Viana, S. D., Nunes, S., & Reis, F. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101123 · Cited by 185
“These findings are in line with the high-levels of pro-inflammatory cytokines (e.g. IL-1, IL-2, IL-7, G-CSF, IP-10, MCP-1, MIP-1A and TNFα) observed in COVID19 severe cases (Huang et al., 2020).”
Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes
Bonafè, M., Prattichizzo, F., Giuliani, A., Storci, G., Sabbatinelli, J., & Olivieri, F. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.04.005 · Cited by 184
SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?
Woodby, B., Arnold, M. M., & Valacchi, G. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14512 · Cited by 160
Abplanalp, W. T., Mas-Peiro, S., Cremer, S., John, D., Dimmeler, S., & Zeiher, A. M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2468 · Cited by 141
The looming storm: Blood and cytokines in COVID-19
Kaur, S., Bansal, R., Kollimuttathuillam, S., Gowda, A. M., Singh, B., Mehta, D., & Maroules, M. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100743 · Cited by 113
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Dagotto, G., Yu, J., & Barouch, D. H. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.08.002 · Cited by 103
“Existing pathogenesis studies suggest that the excessive production of proinflammatory cytokines and chemokines (cytokine storm) is associated with poor clinical outcome (Channappanavar and Perlman, 2017).”
Retracted: Neutrophil/lymphocyte ratio—A marker of COVID‐19 pneumonia severity
(2020) · doi:10.1111/ijcp.13698 · Cited by 88
RetractedClough, E., Inigo, J., Chandra, D., Chaves, L., Reynolds, J. L., Aalinkeel, R., Schwartz, S. A., Khmaladze, A., & Mahajan, S. D. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10015-6 · Cited by 75
“2021; Channappanavar and Perlman 2017)).”
Potential mechanisms of hemorrhagic stroke in elderly COVID-19 patients
Wang, H., Tang, X., Fan, H., Luo, Y., Song, Y., Xu, Y., & Chen, Y. (2020) · Aging · doi:10.18632/aging.103335 · Cited by 69
“com 10025 AGING chemokines involved in the pathogenicity of SARSCoV-2 [50].”
BackgroundInfluentialCOVID 19 Vaccines: Should we fear ADE?
Halstead, S. B., & Katzelnick, L. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa518 · Cited by 69
Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis
Omran, H. M., & Almaliki, M. S. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.06.004 · Cited by 45
Role of senescence in the chronic health consequences of COVID-19
Wissler Gerdes, E. O., Vanichkachorn, G., Verdoorn, B. P., Hanson, G. J., Joshi, A. Y., Murad, M. H., Rizza, S. A., Hurt, R. T., Tchkonia, T., & Kirkland, J. L. (2022) · Translational Research · doi:10.1016/j.trsl.2021.10.003 · Cited by 38
“An excessive inflammatory response to COVID-19 can lead to the worsening of infection and symptoms and, eventually, cytokine storm.(111)”
Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021) · European Journal of Immunology · doi:10.1002/eji.202149181 · Cited by 25
Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles
Crum, R. J., Huckestien, B. R., Dwyer, G., Mathews, L., Nascari, D. G., Hussey, G. S., Turnquist, H. R., Alcorn, J. F., & Badylak, S. F. (2023) · Science Advances · doi:10.1126/sciadv.adf9016 · Cited by 25
Aljuhani, A., Albalawi, O., Albalawi, R., Alsalama, R., Alatawi, S., Altemani, R., Abdel‐Maksoud, M. S., & Elsherbiny, N. (2023) · Cell Biology International · doi:10.1002/cbin.12014 · Cited by 12
“This hyperactivity causes an imbalance between the two types of cytokines: anti‐inflammatory and proinflammatory (Channappanavar & Perlman, 2017) (Shimabukuro‐Vornhagen et al., 2018).”
BackgroundSARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE: COVID-19 and Hematology
Kreidieh, F., & Temraz, S. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.078 · Cited by 7
Metadata
- Authors
- Channappanavar, R., & Perlman, S.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Perlman, Stanley
- Venue
- Seminars in Immunopathology
- Published
- 2017-05-02
- Volume
- 39
- Issue
- 5
- Pages
- 529-539
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- PMC
- PMC7079893
- OpenAlex
- W2610356532
- Cited by
- 2,524
- References
- 129
- Citations by year
- 2026: 27 · 2025: 64 · 2024: 113 · 2023: 208 · 2022: 361 · 2021: 728 · 2020: 996 · 2019: 12 · 2018: 7 · 2017: 7
- FWCI
- 42.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Seminars in Immunopathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI091322, P01AI060699)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- human coronaviruses, cytokine storm, immunopathology, SARS-CoV, MERS-CoV, acute lung injury, acute respiratory distress syndrome, viral pneumonia, inflammatory cytokines, chemokines, immune dysregulation, lower respiratory tract infection
- MeSH terms
- Animals, Antiviral Agents, Combined Modality Therapy, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Immunity, Innate, Interferons, Lung, Macrophages, Monocytes, Phenotype, Severity of Illness Index, Virus Replication, Cytokines, Coronavirus, Coronavirus Infections, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.